Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03845166 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03845166 · ClinicalTrials.gov record · last posted 2024-11-19

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Study acronym: STELLAR-001
StatusActive, Not Recruiting
PhasePhase 1
SponsorExelixis
Started2019-03-20
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

Amendment record 27 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 27 times since 2019-02-18; most recent amendment 2024-11-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-11-06
Status change Recruiting→Active, Not Recruitingv25
2019-02-20
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT03845166
Lead Sponsor Exelixis
Conditions Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Enrollment 325 participants
Start Date 2019-03-20
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-19